Fingolimod: 'Hint' of advantages in a small group of patients
The immunosuppressive drug fingolimod (trade name: Gilenya) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform ...
Jul 5, 2012
0
0